U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative ColitisBusiness Wire • 09/27/23
Takeda Announces Approval of CUVITRU™ Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or HypogammaglobulinemiaBusiness Wire • 09/25/23
Takeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)Business Wire • 09/20/23
Takeda Commits Over $30 Million in Five New Global CSR Partnerships To Further Drive Health Impact in 92 CountriesBusiness Wire • 09/13/23
Takeda Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's DiseaseBusiness Wire • 09/13/23
Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a Highly Selective Oral TYK2 Inhibitor, for the Treatment of Active Psoriatic ArthritisBusiness Wire • 09/11/23
ImmunoGen Announces Collaboration with Takeda to Develop and Commercialize ELAHERE® in JapanBusiness Wire • 08/28/23
Takeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch ProductsBusiness Wire • 07/27/23
Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual MeetingBusiness Wire • 06/20/23
Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The LancetBusiness Wire • 06/16/23
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines AgencyBusiness Wire • 06/15/23
Takeda to Present Oncology Portfolio and Pipeline Data at the 2023 ASCO Annual Meeting and EHA CongressBusiness Wire • 05/26/23
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority ReviewBusiness Wire • 05/25/23
KSQ Therapeutics and Takeda Expand Strategic Immuno-Oncology Collaboration to Identify and Validate Novel Tumor TargetsBusiness Wire • 05/17/23
U.S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)Business Wire • 05/17/23